Home
About
Programs & Pipeline
Lysosomal Storage Disease
Ataxias
Neuro-Oncology
Science & Technology
AAV CAPSID
AAV VECTOR
News
Careers
Contact Us
Select Page
AMY GRIFFIN
by
lacerta2022
|
Sep 14, 2023
Search for:
About Lacerta
Lacerta has quickly become a nationally recognized partner in the development of genetic-based medicines & treatments for central nervous system and lysosomal storage diseases.
Recent Posts
Concept Companies Leads Development Efforts on Second Phase for Lacerta Therapeutics in Alachua’s Progress District
Lacerta and Prevail, A Wholly Owned Subsidiary of Lilly, Sign Agreement to Develop Novel AAV Capsids for CNS Disorders
Tech Tuesday: Gene Therapy